<DOC>
	<DOCNO>NCT01718678</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Melatonin treatment fatigue Quality Life MS patient .</brief_summary>
	<brief_title>Effect Melatonin Multiple Sclerosis Related Fatigue</brief_title>
	<detailed_description>Multiple Sclerosis ( MS ) one common non-traumatic cause disability world . It chronic inflammatory demyelinate disorder Central Nervous System ( CNS ) affect individual productive age cause large burden year come . Fatigue common complaint one least understood symptom MS</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>1. definite diagnosis relapsingremitting MS ( RRMS ) MacDonald criterion 2. baseline Expanded Disability Status Score ( EDSS ) less 5.0 3. age 18 55 year either sex 4. treat one type interferon beta1a ( IFNB1a ) ; 5. sign inform consent 1. clinical relapse MS past 30 day ; 2. use melatonin warfarin within 30 day prior participation ; 3. concomitant use betablockers , antidiabetic agent , antiplatelet agent , NSAIDS , aspirin ; 4. work one nighttime shift per month ; 5 . Pregnancy lactation ; 6. history chronic hematological , cardiac , hepatic , renal thyroid disorder ; 7. failure adhere study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Melatonin</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Quality life</keyword>
</DOC>